• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症恶病质的诊断标准:数据与教条

Diagnostic criteria for cancer cachexia: data versus dogma.

作者信息

Martin Lisa

机构信息

Department of Agricultural, Food & Nutritional Science, University of Alberta, Edmonton, Alberta, Canada.

出版信息

Curr Opin Clin Nutr Metab Care. 2016 May;19(3):188-98. doi: 10.1097/MCO.0000000000000272.

DOI:10.1097/MCO.0000000000000272
PMID:26945342
Abstract

PURPOSE OF REVIEW

Cachexia limits cancer therapy, quality of life, and survival of patients with cancer. Challenges identifying and diagnosing cachexia are due to disparities in diagnostic criteria. A framework for classification of cancer cachexia was recently defined by international consensus. This review describes recent efforts to use this framework to develop definitive diagnostic criteria for cancer cachexia.

RECENT FINDINGS

The principle proposed in the cancer cachexia framework for development of diagnostic criteria is that 'definitive cutoffs for variables could be determined from large contemporary datasets by determining the values that relate optimally to meaningful patient-centered outcomes.' Clearly defined statistical methods to examine distributions of diagnostic criteria in relation to an outcome are used to achieve this task. As a first step, a dataset of more than 11 000 cancer patients from Europe and Canada was compiled, and used to develop and validate a new grading system for cancer-associated weight loss, based on a risk stratification with survival as the outcome. The next refinements for diagnostic criteria will be enabled by the emergence of rich datasets including key variables further specifying the nature of cachexia such as skeletal muscle depletion, reduced food intake, and inflammation.

SUMMARY

Development of diagnostic criteria for cancer cachexia is based on a solid conceptual foundation and is moving toward defining the type of assessments, optimal values, and combinations of criteria that best define cachexia. Large contemporary datasets representing different cancer populations, candidate cachexia diagnostic criteria, and clinical outcomes will further ensure developmental and validation efforts.

摘要

综述目的

恶病质会限制癌症治疗、患者生活质量及癌症患者的生存期。由于诊断标准存在差异,恶病质的识别和诊断面临挑战。最近,国际共识确定了癌症恶病质的分类框架。本综述描述了近期利用该框架制定癌症恶病质明确诊断标准的相关工作。

最新发现

癌症恶病质框架中提出的用于制定诊断标准的原则是,“通过确定与有意义的以患者为中心的结局最相关的值,可从大型当代数据集中确定变量的明确临界值”。为完成此任务,采用了明确的统计方法来检验诊断标准相对于某一结局的分布情况。第一步,收集了来自欧洲和加拿大的11000多名癌症患者的数据集,并用于开发和验证一种新的癌症相关体重减轻分级系统,该系统基于以生存为结局的风险分层。随着包含关键变量(如骨骼肌消耗、食物摄入量减少和炎症等,这些变量进一步明确了恶病质的本质)的丰富数据集的出现,诊断标准将得到进一步完善。

总结

癌症恶病质诊断标准的制定基于坚实的概念基础,并且正朝着确定最能定义恶病质的评估类型、最佳值及标准组合的方向发展。代表不同癌症人群的大型当代数据集、候选恶病质诊断标准及临床结局将进一步确保开发和验证工作的进行。

相似文献

1
Diagnostic criteria for cancer cachexia: data versus dogma.癌症恶病质的诊断标准:数据与教条
Curr Opin Clin Nutr Metab Care. 2016 May;19(3):188-98. doi: 10.1097/MCO.0000000000000272.
2
Definition and classification of cancer cachexia: an international consensus.癌症恶病质的定义和分类:国际共识。
Lancet Oncol. 2011 May;12(5):489-95. doi: 10.1016/S1470-2045(10)70218-7. Epub 2011 Feb 4.
3
Towards a simple objective framework for the investigation and treatment of cancer cachexia: the Glasgow Prognostic Score.建立一个简单的客观框架,用于癌症恶病质的调查和治疗:格拉斯哥预后评分。
Cancer Treat Rev. 2014 Jul;40(6):685-91. doi: 10.1016/j.ctrv.2013.11.007. Epub 2013 Nov 28.
4
Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer.癌症恶病质综合征(CACS)的国际共识定义与晚期非小细胞肺癌患者中心结局之间的相关性
J Pain Symptom Manage. 2015 Apr;49(4):680-9. doi: 10.1016/j.jpainsymman.2014.09.008. Epub 2014 Nov 4.
5
Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model--a study based on data from an international multicentre project (EPCRC-CSA).癌症恶病质共识定义的验证及分类模型的评估——一项基于国际多中心项目(EPCRC-CSA)数据的研究。
Ann Oncol. 2014 Aug;25(8):1635-42. doi: 10.1093/annonc/mdu086. Epub 2014 Feb 20.
6
Defining and classifying cancer cachexia: a proposal by the SCRINIO Working Group.定义和分类癌症恶病质:SCRINIO工作组的一项提议。
JPEN J Parenter Enteral Nutr. 2009 Jul-Aug;33(4):361-7. doi: 10.1177/0148607108325076. Epub 2008 Dec 24.
7
Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients.癌症恶病质的诊断标准:与未经选择的姑息治疗患者的生活质量、运动能力和生存的关系。
Support Care Cancer. 2013 Jun;21(6):1569-77. doi: 10.1007/s00520-012-1697-z. Epub 2013 Jan 13.
8
Cancer cachexia: an overview of diagnostic criteria and therapeutic approaches for the accredited practicing dietitian.癌症恶病质:经认证的执业营养师的诊断标准和治疗方法概述。
J Hum Nutr Diet. 2021 Feb;34(1):243-254. doi: 10.1111/jhn.12811. Epub 2020 Oct 10.
9
Cancer anorexia - cachexia syndrome.癌症厌食-恶病质综合征
Acta Med Indones. 2012 Apr;44(2):154-62.
10
Terminology in cancer cachexia: importance and status.癌症恶病质的术语:重要性和现状。
Curr Opin Clin Nutr Metab Care. 2012 May;15(3):220-5. doi: 10.1097/MCO.0b013e328352a895.

引用本文的文献

1
Diagnostic Criteria for Cancer-Associated Cachexia: Insights from a Multicentre Cohort Study.癌症相关性恶病质的诊断标准:一项多中心队列研究的见解
J Cachexia Sarcopenia Muscle. 2025 Feb;16(1):e13703. doi: 10.1002/jcsm.13703.
2
Weight loss in patients on osimertinib for metastatic EGFR-mutant non-small cell lung cancer.使用奥希替尼治疗转移性表皮生长因子受体(EGFR)突变型非小细胞肺癌患者的体重减轻情况。
Oncologist. 2024 Dec 19. doi: 10.1093/oncolo/oyae315.
3
ZIP4: a promising early diagnostic and therapeutic targets for pancreatic cancer.锌转运蛋白4:胰腺癌一个有前景的早期诊断和治疗靶点。
Am J Cancer Res. 2024 Sep 25;14(9):4652-4664. doi: 10.62347/AVYM3477. eCollection 2024.
4
Baoyuan Jiedu decoction alleviating cancer cachexia-Induced muscle atrophy by regulating muscle mitochondrial function in mice.保元解毒汤通过调节小鼠肌肉线粒体功能减轻癌症恶病质诱导的肌肉萎缩。
Front Pharmacol. 2022 Aug 19;13:914597. doi: 10.3389/fphar.2022.914597. eCollection 2022.
5
Progress in Research on Antitumor Drugs and Dynamic Changes in Skeletal Muscles.抗肿瘤药物研究进展与骨骼肌的动态变化
Front Pharmacol. 2022 Jul 6;13:893333. doi: 10.3389/fphar.2022.893333. eCollection 2022.
6
Tumor cell anabolism and host tissue catabolism-energetic inefficiency during cancer cachexia.肿瘤细胞合成代谢与宿主组织分解代谢-癌症恶病质期间的能量效率低下。
Exp Biol Med (Maywood). 2022 May;247(9):713-733. doi: 10.1177/15353702221087962. Epub 2022 May 6.
7
Revisiting Cancer Cachexia: Pathogenesis, Diagnosis, and Current Treatment Approaches.重新审视癌症恶病质:发病机制、诊断及当前治疗方法
Asia Pac J Oncol Nurs. 2021 Aug 27;8(5):508-518. doi: 10.4103/apjon.apjon-2126. eCollection 2021 Sep-Oct.
8
Phenotypic features of cancer cachexia-related loss of skeletal muscle mass and function: lessons from human and animal studies.癌症恶病质相关骨骼肌减少和功能丧失的表型特征:来自人体和动物研究的教训。
J Cachexia Sarcopenia Muscle. 2021 Apr;12(2):252-273. doi: 10.1002/jcsm.12678. Epub 2021 Mar 30.
9
Does perioperative oxandrolone improve nutritional status in patients with cachexia related to head and neck carcinoma?围手术期使用氧雄龙能否改善头颈部癌恶病质患者的营养状况?
Laryngoscope Investig Otolaryngol. 2019 May 15;4(3):314-318. doi: 10.1002/lio2.268. eCollection 2019 Jun.
10
Muscle radiodensity loss during cancer therapy is predictive for poor survival in advanced endometrial cancer.癌症治疗过程中肌肉放射性密度的丧失与晚期子宫内膜癌患者的不良预后相关。
J Cachexia Sarcopenia Muscle. 2019 Aug;10(4):814-826. doi: 10.1002/jcsm.12440. Epub 2019 May 15.